<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CELECOXIB <img border="0" src="../images/pr.gif"/></span><br/>(cel-e-cox'ib)<br/><span class="topboxtradename">Celebrex<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent, analgesic, nsaid, cyclooxygenase-2 inhibitor, antipyretic</span><br/><b>Pregnancy Category: </b>C first and second trimesters; D third trimester<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 200 mg, 400 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>NSAID that exhibits antiinflammatory, analgesic, and antipyretic activities. Unlike ibuprofen, inhibits prostaglandin synthesis
         by inhibiting cyclooxygenase-2 (COX-2), but does not inhibit cyclooxygenase-1 (COX-1).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces or eliminates the pain of rheumatoid and osteoarthritis.</p>
<h1><a name="uses">Uses</a></h1>
<p>Relief of S&amp;S of osteoarthritis and rheumatoid arthritis. Treatment of acute pain and primary dysmenorrhea. Reduction of polyp
         formation in familial adenomatous polyposis (FAP), ankylosing spondylitis
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe hepatic impairment; hypersensitivity to celecoxib; asthmatic patients with aspirin triad; advanced renal disease; concurrent
         use of diuretics and ACE inhibitors; anemia; pregnancy (category D) in third trimester; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients who are P450 2C9 poor metabolizers; patients who weigh 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Arthritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100Â–200 mg b.i.d. or 200 mg q.d.<br/><br/><span class="indicationtitle">Acute Pain, Dysmenorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg 1<sup>st</sup> dose, then 200 mg same day if needed, then 200 mg b.i.d. prn<br/><br/><span class="indicationtitle">FAP</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg b.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give 2 h before/after magnesium or aluminum-containing antacids.</li>
<li>Store in tightly closed container and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Back pain, peripheral edema. Increased risk of cardiovascular events. <span class="typehead">GI:</span> Abdominal pain, diarrhea, dyspepsia, flatulence, nausea. <span class="typehead">CNS:</span> Dizziness, headache, insomnia. <span class="typehead">Respiratory:</span> Pharyngitis, rhinitis, sinusitis, URI. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May diminish effectiveness of <span class="classification">ace inhibitors</span>; <b>fluconazole</b> increases celecoxib concentrations; may increase <b>lithium</b> concentrations; may increase INR in older patients on <b>warfarin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Peak:</span> 3 h. <span class="typehead">Distribution:</span> 97% protein bound; crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochrome P450 2C9 enzymes. <span class="typehead">Elimination:</span> Excreted primarily in feces (57%), 27% excreted in urine. <span class="typehead">Half-Life:</span> 11.2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Therapeutic effectiveness is indicated by relief of joint pain.</li>
<li>Lab tests: Periodically monitor Hct and Hgb, liver functions, BUN and creatinine, and serum electrolytes.</li>
<li>Monitor closely lithium levels when the two drugs are given concurrently.</li>
<li>Monitor closely PT/INR when used concurrently with warfarin.</li>
<li>Monitor for fluid retention and edema especially in those with a history of hypertension or CHF.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid using celecoxib during the third trimester of pregnancy.</li>
<li>Promptly report any of the following: unexplained weight gain, edema, skin rash.</li>
<li>Stop taking celecoxib and promptly report to physician if any of the following occurs: S&amp;S of liver dysfunction including
            nausea, fatigue, lethargy, itching, jaundice, abdominal pain, and flulike symptoms; S&amp;S of GI ulceration including black,
            tarry stools and upper GI distress.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>